683 Capital Management’s Galmed Pharmaceuticals GLMD Stock Holding History

683 Capital Management’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-543	Closed	-$2.71M	–	150
2020 Q1	$2.71M	Sell	543 -13	-2%	-$98.9K	0.32%	63
2019 Q4	$4.62M	Sell	556 -386	-41%	-$2.65M	0.53%	46
2019 Q3	$6.48M	Buy	942 +4	+0.4%	+$32.1K	0.72%	32
2019 Q2	$9.92M	Hold	938	–	–	0.9%	32
2019 Q1	$11M	Hold	938	–	–	1%	22
2018 Q4	$9.22M	Hold	938	–	–	0.56%	41
2018 Q3	$18.3M	Hold	938	–	–	1.19%	19
2018 Q2	$16.1M	Buy	938 +487	+108%	+$5.64M	1.09%	23
2018 Q1	$3.62M	Hold	451	–	–	0.32%	64
2017 Q4	$5.94M	Buy	451 +70	+18%	+$827K	0.5%	56
2017 Q3	$5.02M	Buy	381 +34	+10%	+$376K	0.53%	53
2017 Q2	$3.1M	Hold	347	–	–	0.46%	57
2017 Q1	$2.44M	Buy	347 +45	+15%	+$287K	0.38%	58
2016 Q4	$1.52M	Buy	302 +83	+38%	+$438K	0.11%	88
2016 Q3	$1.4M	Buy	219 +99	+83%	+$597K	0.15%	71
2016 Q2	$779K	Sell	120 -64	-35%	-$484K	0.12%	62
2016 Q1	$1.3M	Hold	184	–	–	0.23%	47
2015 Q4	$2.01M	Hold	184	–	–	0.28%	61
2015 Q3	$1.97M	Hold	184	–	–	0.29%	57
2015 Q2	$2.66M	Hold	184	–	–	0.55%	50
2015 Q1	$2.49M	Sell	184 -2	-1%	-$24K	0.95%	35
2014 Q4	$1.55M	Buy	186 +13	+8%	+$113K	0.68%	36
2014 Q3	$2.14M	Sell	173 -11	-6%	-$120K	0.73%	35
2014 Q2	$2.58M	Buy	184 +74	+67%	+$909K	0.97%	31
2014 Q1	$1.82M	Buy	+110	New	+$2.06M	0.71%	34

Other funds holding GLMD

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

683 Capital Management's GLMD Position: Q2 2020 in Review

683 Capital Management sold out of Galmed Pharmaceuticals (GLMD) in Q2 2020, closing a stake of 543 shares — an estimated $2.71M sold.

683 Capital Management first reported a position in GLMD in Q1 2014 and held it in 25 quarters. The position peaked at $18.3M in Q3 2018. 21 funds tracked by Wall St. Rank hold GLMD as of Q2 2020.

683 Capital Management reported no remaining Galmed Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
683 Capital Management sold 543 Galmed Pharmaceuticals shares in Q2 2020, an estimated $2.71M.
683 Capital Management first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 25 quarters.
683 Capital Management's Galmed Pharmaceuticals position peaked at $18.3M in Q3 2018.
21 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2020.

Based on 683 Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.